Latest news
Long-Term Follow-Up Shows Safety Signal for OXB-102 Gene Therapy in Parkinson Disease - NeurologyLiveNeurologyLive · Sat, 08 Aug 2026 22:07:30 GMTOxford BioMedica (LSE:OXB): What’s Driving Market Attention? - Kalkine MediaKalkine Media · Fri, 07 Aug 2026 09:03:00 GMTOxford BioMedica tanks 24% after earnings alert; brokers take stock - Proactive InvestorsProactive Investors · Fri, 07 Aug 2026 08:03:00 GMTOxford Biomedica Shares Slump on Deep FY2026 Revenue Downgrade - AskTradersAskTraders · Fri, 07 Aug 2026 07:43:51 GMTRNS Hotlist with Zak Mir: GDWN, AXL, TLM, OXB, GELN & AMRQ - Share TalkShare Talk · Fri, 07 Aug 2026 07:40:52 GMTOxford Biomedica Lowers 2026 Guidance Despite Strong Client Growth - Yahoo Finance UKYahoo Finance UK · Fri, 07 Aug 2026 07:32:19 GMTOxford Biomedica cuts 2026 revenue guidance as clients delay orders - Proactive financial newsProactive financial news · Fri, 07 Aug 2026 07:17:08 GMTOxford Biomedica Lowers FY 2026 Revenue Forecast to £180-200m Amid Client Ordering Changes and Durham Facility Delay - Kalkine MediaKalkine Media · Fri, 07 Aug 2026 06:01:17 GMT